Australian and European Union Mutual Recognition Agreement (MRA) to be delayed until December:
This article was originally published in Clinica
Final implementation of the mutual recognition agreement between Australia and the EU may not now occur until December. Due legislative procedures in the European Parliament, as well as the proposal by Australia's Therapeutic Goods Administration that an 18-month confidence-building period should be built into the process, are likely to delay introduction of the MRA.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.